A 35-year-old woman of Gujarati descent is found to have mild microcytic anemia (Hb 10.5 g/dL, MCV 68 fL) on routine screening. She is asymptomatic with no hepatosplenomegaly. Her 8-year-old daughter has beta-thalassemia major on transfusion therapy. Peripheral blood smear shows target cells and mild anisopoikilocytosis. Hemoglobin electrophoresis reveals: HbA 92%, HbA₂ 4.2%, HbF 1.5%. Serum ferritin is normal. What is the most likely diagnosis?

## Diagnosis: Beta-Thalassemia Trait (Heterozygous Beta-Thalassemia) ### Clinical Context **Key Point:** Beta-thalassemia trait (BTT) is the **heterozygous state** (one normal β-globin allele, one mutant allele) and is typically asymptomatic with mild microcytic anemia discovered incidentally. This 35-year-old woman presents with: - **Asymptomatic** presentation (no symptoms, no organomegaly) - **Mild microcytic anemia** (Hb 10.5 g/dL, MCV 68 fL) — within the range of BTT - **Family history** of beta-thalassemia major (daughter) — confirms carrier status - **Target cells on smear** — characteristic of thalassemia trait - **Normal serum ferritin** — excludes iron deficiency anemia ### Hemoglobin Electrophoresis: The Diagnostic Gold Standard **High-Yield:** The electrophoresis pattern is **diagnostic** for BTT: | HbA | HbA₂ | HbF | Interpretation | |-----|------|-----|----------------| | 92% | 4.2% | 1.5% | **Beta-thalassemia trait** | **Key Point:** The **elevated HbA₂ (>3.5%)** is the hallmark of BTT. This occurs because: 1. One β-globin allele is mutant → reduced β-globin chain synthesis 2. Unpaired α-globin chains pair with δ-globin chains → HbA₂ (α₂δ₂) increases 3. Compensatory γ-globin activation is mild → HbF slightly elevated (1–3%) ### Pathophysiology of BTT ```mermaid flowchart TD A[Heterozygous β-globin mutation]:::outcome --> B[One normal allele produces ~50% normal β-chains]:::outcome B --> C[Unpaired α-chains accumulate mildly]:::outcome C --> D[δ-globin chains pair with excess α-chains]:::action D --> E[HbA₂ increases to 3.5-5.5%]:::outcome C --> F[γ-globin activation is minimal]:::action F --> G[HbF mildly elevated 1-3%]:::outcome E --> H[Mild microcytic anemia]:::outcome G --> H ``` ### Laboratory Findings in BTT | Parameter | BTT Range | This Patient | Significance | |-----------|-----------|--------------|-------------| | Hb | 10–13 g/dL | 10.5 g/dL | Mild anemia | | MCV | 60–75 fL | 68 fL | Microcytic | | RBC count | 4.5–6.0 × 10¹²/L | (not given) | Normal to elevated | | Reticulocyte count | 1–2% | (not given) | Normal (no hemolysis) | | HbA | 80–95% | 92% | Reduced but present | | HbA₂ | 3.5–5.5% | 4.2% | **Elevated (diagnostic)** | | HbF | 0.5–2% | 1.5% | Mildly elevated | | Serum ferritin | Normal | Normal | No iron overload | | Serum iron, TIBC | Normal | (not given) | Normal iron metabolism | ### Clinical Pearl **Key Point:** BTT is **clinically benign** and requires **no treatment**. However, genetic counseling is essential: - If both parents are BTT carriers → 25% risk of BTM in offspring - This patient's daughter with BTM confirms she is a carrier - Partner screening is recommended for family planning ### Mnemonic: BTT vs BTI vs BTM **"HAFT" — HbA₂ & F Trends:** - **BTT (Trait):** HbA₂ **↑↑** (3.5–5.5%), HbF normal/mild ↑, **Hb 10–13 g/dL**, asymptomatic - **BTI (Intermedia):** HbA₂ ↑, HbF ↑↑, **Hb 7–10 g/dL**, transfusion-independent - **BTM (Major):** HbA absent, HbF ↑↑↑ (>70%), **Hb <7 g/dL**, transfusion-dependent [cite:Robbins 10e Ch 14]